Table 2

Demographics and baseline characteristics of study cohort

Baseline characteristicsAll patients
(n=23293)
Medication category
Additional add-on therapies
(n=3816)
High-dose therapies
(n=18596)
Continuous or frequent use of oral steroids (n=881)
Female, n (%)13879 (60)2471 (65)10855 (58)553 (63)
Mean age at index, (SD)50 (14)50 (14)50 (14)53 (13)
BMI (kg/m2), n (%)
 Underweight272 (1)51 (1)203 (1)18 (2)
 Normal weight4710 (20)783 (21)3751 (20)176 (20)
 Overweight6092 (26)988 (26)4886 (26)218 (25)
 Obese5796 (25)922 (24)4633 (25)241 (27)
 Severely obese1378 (6)235 (6)1079 (6)64 (7)
Smoking status, n (%)
 Current smoker6610 (28)955 (25)5392 (29)263 (30)
 Non-smoker/never13618 (58)2335 (61)10779 (58)504 (57)
 Ex-smoker2961 (13)512 (13)2337 (13)112 (13)
Region, n (%)
 North East528 (2)79 (2)423 (2)26 (3)
 North West4208 (18)600 (16)3463 (19)145 (16)
 Yorkshire and The Humber1139 (5)146 (4)964 (5)29 (3)
 East Midlands942 (4)95 (2)815 (4)32 (4)
 West Midlands2912 (13)479 (13)2317 (12)116 (13)
 East of England2402 (10)485 (13)1815 (10)102 (12)
 South West3079 (13)567 (15)2357 (13)155 (18)
 South Central3283 (14)475 (12)2669 (14)139 (16)
 London2356 (10)412 (11)1879 (10)65 (7)
 South East Coast2444 (10)478 (13)1894 (10)72 (8)
Mean number of OCS prescriptions in the year prior, (SD)2 (5)3 (7)2 (3)12 (12)
Mean eosinophil count (×109/L), (SD)0.24 (0.13)0.24 (0.13)0.24 (0.13)0.24 (0.14)
Asthma attacks in the year prior,
n (%)
 11492 (6)275 (7)1074 (6)143 (16)
 2 or more489 (2)124 (3)260 (1)105 (12)
1+ asthma hospitalisations in the year prior, n (%)872 (4)138 (4)666 (4)68 (8)
  • BMI, body mass index; OCS, oral corticosteroid.